Effect of Valsartan on Carotid Artery Disease

NCT ID: NCT00208767

Last Updated: 2015-12-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-02-28
• Study Completion Date: 2009-11-30

Brief Summary

The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible for repair of the vessel wall, reduce oxidation and inflammation, improve the function of the blood vessels, and arrest or slow down the progression of atherosclerosis over time.

Detailed Description

Atherosclerosis or 'hardening of the arteries' is a process that ultimately leads to the development of heart attacks, strokes, poor circulation, and death. Millions of Americans are affected by this progressive disease of the arteries. Researchers have tried to understand the very complex processes that lead to hardening of the arteries. Part of this research has taught the investigators that there are specific molecules that can cause damage or injury to the vessel wall by increasing oxidation and inflammation which, in turn, leads to atherosclerosis. Other molecules and cells have been found that can actually repair the vessel wall.

Currently, the best treatment the investigators have for preventing or slowing atherosclerosis is to control the patients' risk factors such as high blood pressure, diabetes, or cholesterol levels using prevention and specific drugs. Angiotensin receptor blockers (ARBs) are a class of drugs that have been shown in clinical trials to have many beneficial effects in patients with high blood pressure, advanced heart diseases (such as after heart attack and heart failure), and diabetes. However, whether these drugs will also be useful in people with early signs of hardening of the arteries, measured as a thickening of the carotid (neck) arteries is unknown, and is the purpose of this study.

The EFFERVESCENT trial is designed to evaluate the effects of a specific ARB, called valsartan, on atherosclerosis. The investigators want to know if treatment with valsartan will increase the blood levels of markers responsible for repair of the vessel wall, reduce oxidation and inflammation, improve the function of the blood vessels, and arrest or slow down the progression of atherosclerosis over time.

In this study, the investigators will recruit subjects who have a hardening or thickening of their carotid arteries, one of the main blood vessels in the neck. People will be screened with ultrasound or sonar examination for this. Two-thirds of those eligible for participation will receive valsartan while the remaining one-third will receive a placebo pill. The investigators and subjects will be unaware of which drug is being given until the end of the study. The study will last for 2 years. Half of the individuals will also be treated with a statin drug (used for cholesterol reduction) and the remaining individuals will not be on a statin.

The investigators will measure carotid artery thickening with magnetic resonance imaging (MRI); forearm blood vessel function using ultrasound; and they will perform blood tests to measure oxidation and inflammation in the blood stream and circulation stem cells that are responsible for healing. These tests will be repeated at 3 months, 1 year and 2 years after starting treatment. The investigators will also collect blood for genotyping where the DNA will be stored for future analysis to study whether subjects' genotype alters their susceptibility to treatments. The investigators' hypothesis is that ARB treated individuals will have less oxidation and inflammation, higher levels of stem cells, and a slower progression of arterial thickening.

Finding an early treatment for atherosclerosis would hopefully prevent future strokes, heart attacks, and deaths leading to improved longevity and reduced medical expenditure.

Conditions

Carotid Artery Diseases; Atherosclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Valsartan

Valsartan titrated up to 320 mg orally daily

Group Type: ACTIVE_COMPARATOR

Valsartan

Intervention Type: DRUG

Valsartan was titrated to a target dose of 320 mg orally daily

Placebo

Patients received a placebo instead of Valsartan

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

A matched placebo pill will be given orally daily.

Interventions

Valsartan

Valsartan was titrated to a target dose of 320 mg orally daily

Intervention Type: DRUG

Placebo

A matched placebo pill will be given orally daily.

Intervention Type: DRUG

Other Intervention Names

Diovan is a brand name of Valsartan

Eligibility Criteria

Inclusion Criteria

• > 0.65 mm intima-media thickness of the carotid artery measured by ultrasound
• Males aged 21-80 years or women without child bearing potential up to age 80
• Can be on concomitant therapy with aspirin, thiazide diuretics, calcium antagonists (for treatment of hypertension), or beta-receptor antagonists.
• May be on statin if on stable dose for at least 2 months before recruitment

Exclusion Criteria

• Angiotensin-converting enzyme (ACE) inhibitor or ARB therapy in the previous 3 months.
• Initiation or change in dose of statin therapy within 2 months before the study
• Inability to return to Emory for follow-up blood drawing and MR imaging
• Age < 21 or > 80 years
• Premenopausal females with potential for pregnancy
• Current neoplasm
• Chronic renal failure [creatinine > 2.5 mg/dL]
• Diabetes with hemoglobin (Hb) A1c > 8.5
• Anticipated change in lipid lowering therapy
• Inability to give informed consent
• Blood pressure > 140 mmHg systolic and > 90 mmHg diastolic
• Low-density lipoprotein (LDL) cholesterol level >130 mg/dl
• Acute coronary syndrome within 2 months
• Acute cerebrovascular accident within 2 months

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Emory University

OTHER

Sponsor Role: lead

Responsible Party

Arshed A. Quyyumi

Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Arshed Quyyumi, MD

Role: PRINCIPAL_INVESTIGATOR

Emory University

Locations

Emory University School of Medicine

Atlanta, Georgia, United States

Countries

United States

Other Identifiers

CVAL489AUS51

Identifier Type: OTHER

Identifier Source: secondary_id

IRB00024913

Identifier Type: -

Identifier Source: org_study_id